Pretomanid is the "Pa" in the modern short oral regimens BPaL and BPaLM for highly resistant tuberculosis, and identifying its target separates it from its regimen partners.
It is a $\textbf{nitroimidazo-oxazine prodrug}$ that must first be reduced intracellularly by the F420-dependent nitroreductase $\text{Ddn}$. This bioactivation explains its two complementary killing modes. In dividing aerobic bacilli it $\textbf{blocks mycolic acid biosynthesis}$, crippling assembly of the waxy mycobacterial cell wall. In dormant, non-replicating bacilli under anaerobic conditions, the activated drug liberates $\textbf{reactive nitrogen intermediates such as nitric oxide}$ that disrupt respiration and sterilise persistent organisms.
The decoys correspond to its companion drugs and standard agents: rifampicin hits RNA polymerase ($rpoB$), bedaquiline ($B$) blocks mycobacterial ATP synthase, and fluoroquinolones ($L$ = linezolid is a ribosomal agent, while moxifloxacin) target DNA gyrase. None of these is pretomanid’s action.
\[\boxed{\text{Pretomanid: inhibits mycolic acid synthesis + releases reactive nitrogen species}}\]